Drug
ACY-1215
ACY-1215 is a pharmaceutical drug with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 80.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
80.0%
Based on 4 completed trials
Completion Rate
80%(4/5)
Active Trials
1(17%)
Results Posted
25%(1 trials)
Terminated
1(17%)
Phase Distribution
Ph phase_1
6
100%
Phase Distribution
6
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
6(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
6
all time
Status Distribution
Active(1)
Completed(4)
Terminated(1)
Detailed Status
Completed4
Active, not recruiting1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
1
Success Rate
80.0%
Most Advanced
Phase 1
Trials by Phase
Phase 16 (100.0%)
Trials by Status
completed467%
active_not_recruiting117%
terminated117%
Recent Activity
1 active trials
Showing 5 of 6
active_not_recruitingphase_1
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
NCT02787369
terminatedphase_1
ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
NCT02091063
completedphase_1
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
NCT01583283
completedphase_1
ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer
NCT02632071
completedphase_1
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
NCT01323751
Clinical Trials (6)
Showing 6 of 6 trials
NCT02787369Phase 1
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
NCT02091063Phase 1
ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
NCT01583283Phase 1
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
NCT02632071Phase 1
ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer
NCT01323751Phase 1
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
NCT02088398Phase 1
Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy Subjects
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6